Amy C. Peterson sold $3.3M of EXEL
EVP Prod Dev & Med Aff & CMO at EXELIXIS, INC.. 72,776 shares at an average of $45.47, traded May 16, 2025, filed May 16, 2025.
Score components
- +15RoleOfficer
- +25Trade size$3.3M at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000939767-25-000076, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2025 | FTax withholding Common Stock | -8,303 | $44.65 | $371k | 498,169 | May 16, 2025 |
| May 16, 2025 | MOption exercise Common Stock | +40,000 | $21.75 | $870k | 538,169 | May 16, 2025 |
| May 16, 2025 | SOpen-market sale Common Stock | -72,776 | $45.47 | $3.3M | 465,393 | May 16, 2025 |
| May 16, 2025 | MOption exercise Option (right to buy)derivative | -40,000 | $0.00 | $0 | 120,000 | May 16, 2025 |
Related signals
Other insiders at EXELIXIS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | EXELIXIS, INC. | Jack L Wyszomierski director | $325k 7,535 shares | -2% | |
| 42Moderate | EXELIXIS, INC. | Sue Gail Eckhardt director | $805k 18,838 shares | -47% | |
| 47Moderate | EXELIXIS, INC. | Tomas J. Heyman director | $201k 4,544 shares | -12% | |
| 55Moderate | EXELIXIS, INC. | Patrick J. Haley EVP, Commercial | $1.5M 34,387 shares | -8% | |
| 30Weak | EXELIXIS, INC. | Patrick J. Haley EVP, Commercial | $6.5M 136,383 shares | -27% | |
| 55Moderate | EXELIXIS, INC. | Jeffrey Hessekiel EVP & General Counsel | $1.2M 25,000 shares | -3% | |
| 40Moderate | EXELIXIS, INC. | Stelios Papadopoulos director | $1.6M 36,508 shares | -3% | |
| 47Moderate | EXELIXIS, INC. | Christopher J. Senner EVP and CFO | $4.6M 100,000 shares | -9% | |
| 44Moderate | EXELIXIS, INC. | George Poste director | $949k 20,634 shares | -11% | |
| 17Weak | EXELIXIS, INC. | Dana Aftab CSO/EVP Disc & Trans Research | $59k 1,508 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.